• Explore /
  • Poster
  • / A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

Abstract Poster

Authors

null

P. Moreau

CHRU Nantes, Nantes, France

P. Moreau , A. P. Palumbo , A. K. Stewart , V. Rajkumar , A. J. Jakubowiak , K. Halka , S. Goranov , H. Bumbea , K. B. Pendergrass , A. Lupu , A. Dimopoulos , A. O. Rocafiguera , J. G. Gandhi , G. Mihaylov , T. Masszi , J. Matous , G. Fonseca , R. Bryce , D. S. D. Siegel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session

Track

Special Sessions,Clinical Trials

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01080391

Citation

J Clin Oncol 29: 2011 (suppl; abstr TPS225)

Abstract #

TPS225

Poster Bd #

51G

Abstract Disclosures

Similar Posters

First Author: Heinz Ludwig

First Author: Meletios A. Dimopoulos

First Author: Andrew Jenho Yee

First Author: Frederic J. Reu